drugset / Trial / NCT07350421

The Effectiveness of Inhaled Salbutamol in the Management of Transient Tachypnea of the Newborn(TTN)

NCT07350421

Not yet recruiting 1 enrolled Latakia University
RandomizedParallel-groupSingle-blindTreatment

Summary

TTN is the most common respiratory disorder in the perinatal period, causing 40% of cases of respiratory distress after birth. Lung fluid absorption is initiated by beta-adrenergic agonists, such as endogenous steroids and Catecholamine, which increase during labor. Delayed absorption of fluid from the lungs is thought to be the primary mechanism of transient tachypnea of the newborn (TTN). The accumulation of fluid within the lungs impairs gas exchange, leading to increased respiratory effort. Tachypnea develops to compensate for this, and hypoxemia develops due to impaired alveolar ventilation . The main objective of the study: To study the effectiveness of salbutamol in improving signs of respiratory distress according to the modified Downes score during the first 72 hours of life in infants with transient tachypnea of the newborn (TTN). Secondary objectives: Duration of tachypnea (time to resolution of respiratory distress) Reducing the duration of the need for oxygen support Reducing the length of hospital stay

Timeline

Start
2026-01-01
Primary completion
2027-01-01
Completion
2028-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Salbutamol Unknown 0.15 mg/kg Inhaled

Indications

No indication recorded.